Today: 10 June 2026
Browse Category

Space Exploration 2 January 2026 - 30 May 2026

Blue Origin Launch and SpaceX IPO Hype Set Stage for Tema Space ETF Activity

Blue Origin Launch and SpaceX IPO Hype Set Stage for Tema Space ETF Activity

Tema Space Innovators ETF closed Friday at $40.17, down 3.97% after a Blue Origin rocket explosion triggered a selloff in space stocks. Despite the drop, the ETF gained about 3.6% for the shortened week. SpaceX secured a $4.16 billion U.S. Space Force contract and plans to start its IPO roadshow June 4, with shares possibly available as soon as June 11.
30 May 2026
········
Tema NASA ETF Watch as SpaceX IPO Talk Grows

Tema NASA ETF Watch as SpaceX IPO Talk Grows

Tema Space Innovators ETF fell 3.9% to $34.51 Friday but gained 7.5% for the week. The fund holds $707.3 million in assets, with Rocket Lab and SpaceX SPV among top positions. Reuters reported SpaceX may file for a Nasdaq IPO as soon as next week, targeting a $1.75 trillion valuation. SpaceX shareholders approved a 5-for-1 stock split, effective the week of May 18.
16 May 2026
·····
Blue Origin Just Reused New Glenn — and Landed the Booster in a SpaceX Challenge

Blue Origin Just Reused New Glenn — and Landed the Booster in a SpaceX Challenge

Blue Origin landed a reused New Glenn booster in the Atlantic after launching AST SpaceMobile’s BlueBird 7 satellite from Cape Canaveral at 7:25 a.m. EDT Sunday. The booster, previously flown in November, returned to the sea platform Jacklyn about 10 minutes after liftoff. The mission marks Blue Origin’s first recovery of a New Glenn booster after a second flight. BlueBird 7 aims to expand space-based cellular broadband for ordinary smartphones.
19 April 2026
·
Why Intuitive Machines (LUNR) stock is up today: NASA Artemis II tracking role, fresh $26 target

Why Intuitive Machines (LUNR) stock is up today: NASA Artemis II tracking role, fresh $26 target

Intuitive Machines shares surged 13% to $22.91 after announcing NASA selected it to help track the Artemis II mission, though no payments are involved. Trading volume topped 8.5 million shares by early afternoon. KeyBanc raised its price target to $26, maintaining an Overweight rating. Artemis II’s first launch window opens Feb. 6.
28 January 2026
···
NASA pulls Crew-11 from ISS in first medical evacuation as SpaceX Dragon heads for splashdown

NASA pulls Crew-11 from ISS in first medical evacuation as SpaceX Dragon heads for splashdown

A SpaceX Dragon capsule carrying four Crew-11 astronauts undocked from the International Space Station late Wednesday after a crew member developed a medical issue, marking NASA’s first medical evacuation from orbit. NASA has not identified the astronaut or condition but says the situation is stable. The early departure leaves the station with three crew and pauses spacewalks until the next rotation. Splashdown is set for early Thursday off California.
15 January 2026
··
NASA’s Moon Nuclear Reactor Push Meets DOE Safety Rule Shake-Up — What Space and Nuclear Stocks Are Watching

NASA’s Moon Nuclear Reactor Push Meets DOE Safety Rule Shake-Up — What Space and Nuclear Stocks Are Watching

NASA and the Department of Energy plan to deploy a nuclear reactor on the Moon by 2030, according to a new agreement. Energy Secretary Chris Wright has ended the DOE’s ALARA radiation-safety principle. Contractors involved in lunar infrastructure are drawing renewed attention as the agencies push forward. The DOE is also revising nuclear regulations, which could affect project costs and timelines.
14 January 2026
··
Alien Talk Fades Around Interstellar Comet 3I/ATLAS as New Searches Find No Signals and Images Turn Green

Alien Talk Fades Around Interstellar Comet 3I/ATLAS as New Searches Find No Signals and Images Turn Green

Astronomers using the Green Bank Telescope detected no radio technosignatures from interstellar comet 3I/ATLAS, supporting its natural origin. Gemini North released an image showing the comet’s green glow from gases near the Sun. NASA’s Europa Clipper spacecraft observed the comet’s tails in ultraviolet, with some features still unexplained, researchers said.
8 January 2026
Europa Clipper’s UV look at Comet 3I/ATLAS backs water-ice call as radio “technosignature” scan finds none

Europa Clipper’s UV look at Comet 3I/ATLAS backs water-ice call as radio “technosignature” scan finds none

NASA’s Europa Clipper spacecraft detected hydrogen and oxygen in the coma of interstellar comet 3I/ATLAS using its ultraviolet spectrograph in November, the SETI Institute said Tuesday. The comet, only the third known interstellar object to pass through the solar system, showed no signs of breaking apart. Europe’s JUICE mission and the Green Bank Telescope also observed the comet last fall. No artificial radio signals were found.
7 January 2026
Moon rush 2026: Blue Origin, Firefly, Intuitive Machines and Astrobotic line up lunar landings

Moon rush 2026: Blue Origin, Firefly, Intuitive Machines and Astrobotic line up lunar landings

Blue Origin, Firefly Aerospace, Intuitive Machines, and Astrobotic plan robotic lunar landings in 2026, with several missions tied to NASA’s CLPS program. Blue Origin’s Mark 1 aims for Shackleton crater, while Firefly targets the far side and Intuitive Machines eyes Reiner Gamma. NASA’s Artemis II and China’s Chang’e-7 are also set for major Moon missions that year.
6 January 2026
·
Alien-signal hunt finds nothing from interstellar comet 3I/ATLAS after Green Bank scan

Alien-signal hunt finds nothing from interstellar comet 3I/ATLAS after Green Bank scan

Breakthrough Listen researchers found no credible radio technosignatures from interstellar comet 3I/ATLAS after a five-hour Green Bank Telescope search on Dec. 18. The null result comes as scientists examine unusual jet features in Hubble images. NASA confirmed the comet posed no threat, passing 270 million km from Earth. The object was first reported by the ATLAS survey in Chile on July 1, 2025.
5 January 2026
Scientists Scanned Interstellar Comet 3I/ATLAS for Alien Signals — and Found Nothing

Scientists Scanned Interstellar Comet 3I/ATLAS for Alien Signals — and Found Nothing

Breakthrough Listen found no artificial radio signals from interstellar comet 3I/ATLAS after scanning it with the Green Bank Telescope, researchers reported. Harvard’s Avi Loeb highlighted unusual jet patterns in Hubble images and called for further study. NASA maintains the object is a natural comet and poses no threat. The comet is already leaving the solar system, limiting further observations.
4 January 2026
NASA’s Artemis II Moon mission is getting closer — latest on the 2026 launch window

NASA’s Artemis II Moon mission is getting closer — latest on the 2026 launch window

NASA is targeting an initial Artemis II launch window opening Feb. 5, with backup dates through April 2026. The mission will send four astronauts, including Christina Koch and Canadian Jeremy Hansen, on a 10-day lunar flyby aboard the SLS rocket and Orion capsule. NASA may move the rocket to the pad as early as January. Artemis II marks the first crewed flight of SLS and Orion.
3 January 2026
Interstellar comet 3I/ATLAS spills its secrets as scientists clock its water loss and radio silence

Interstellar comet 3I/ATLAS spills its secrets as scientists clock its water loss and radio silence

Astronomers measured water streaming from interstellar comet 3I/ATLAS after its November 2025 solar flyby, with SOHO data showing a peak rate of 3.17×10^29 molecules per second. Breakthrough Listen reported no credible narrowband radio technosignatures from the object. NASA said the comet will not approach closer than 1.8 AU to Earth. Amateur astronomers continue attempts to photograph it.
2 January 2026
·
1 2 3 … 11

Stock Market Today

  • Outlook Therapeutics Shares Jump 26% on FDA Fast-Track Review for Lytenava
    June 10, 2026, 5:57 PM EDT. Outlook Therapeutics shares surged about 26% to $0.89 on heavy volume as the FDA designated its Lytenava (ONS-5010) resubmission a Class 1 review, triggering a faster 60-day decision timeline. The drug targets wet age-related macular degeneration (wet AMD), a vision-impairing condition. The FDA's ruling follows an appeal overturning earlier efficacy concerns and reclassifies the application for expedited review. Despite the stock's gains, Outlook remains below the $1 Nasdaq compliance threshold, raising concerns over dilution. CEO Bob Jahr called the update a testament to the company's strong application. Lytenava, an anti-VEGF therapy, would compete with Roche and Regeneron products in the lucrative U.S. wet AMD market.

Latest articles

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

10 June 2026
Parabilis Medicines soared 58% above its $20 IPO price to close at $31.60 in its Nasdaq debut after raising a record $670 million, reflecting strong investor demand for its Helicon drug platform ahead of a pivotal Phase 3 desmoid tumor trial planned for 2027; Regeneron’s $75 million private placement added credibility.
Joby Aviation Shares Slip After CFO Files to Sell Stock

Joby Aviation Shares Slip After CFO Files to Sell Stock

10 June 2026
Joby Aviation fell 4.47% to $8.86 after CFO Rodrigo Brumana disclosed selling 78,489 shares under a prearranged 10b5-1 plan, with no new certification or commercial-launch updates, leaving investors focused on regulatory progress and cash burn as the key catalysts for the stock.
YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
Go toTop